当前位置: 首页 >> 检索结果
3941. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
作者: Athimalaipet V Ramanan.;Pierre Quartier.;Nami Okamoto.;Ivan Foeldvari.;Alberto Spindler.;Šárka Fingerhutová.;Jordi Antón.;Zhongkai Wang.;Gabriella Meszaros.;Joana Araújo.;Ran Liao.;Stuart Keller.;Hermine I Brunner.;Nicolino Ruperto.; .; .
来源: Lancet. 2023年402卷10401期555-570页
Juvenile idiopathic arthritis can be refractory to some or all treatment regimens, therefore new medications are needed to treat this population. This trial assessed the efficacy and safety of baricitinib, an oral Janus kinase 1/2-selective inhibitor, versus placebo in patients with juvenile idiopathic arthritis.
3944. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
作者: Siow Ming Lee.;Christian Schulz.;Kumar Prabhash.;Dariusz Kowalski.;Aleksandra Szczesna.;Baohui Han.;Achim Rittmeyer.;Toby Talbot.;David Vicente.;Raffaele Califano.;Diego Cortinovis.;Anh Tuan Le.;Dingzhi Huang.;Geoffrey Liu.;Federico Cappuzzo.;Jessica Reyes Contreras.;Martin Reck.;Ramon Palmero.;Milena Perez Mak.;Youyou Hu.;Stefanie Morris.;Elen Höglander.;Mary Connors.;Alice M Biggane.;Hans Kristian Vollan.;Solange Peters.
来源: Lancet. 2023年402卷10400期451-463页
Despite immunotherapy advancements for patients with advanced or metastatic non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 and a median age of 65 years or younger. We aimed to compare the efficacy and safety of first-line atezolizumab monotherapy with single-agent chemotherapy in patients ineligible for platinum-based chemotherapy.
3951. Non-immune hydrops fetalis caused by Diamond-Blackfan anaemia and a mutation of the RPL15 gene.
作者: Pradip Dashraath.;Karen M X Lim.;Hui-Lin Chin.;Azleen Sidek.;Derrick W Q Lian.;Arundhati Gosavi.;Pei Lin Koh.;Arijit Biswas.;Denise L M Goh.
来源: Lancet. 2023年402卷10396期141页 3954. Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham-controlled, multicentre trial.
作者: Gerrit Burkhardt.;Ulrike Kumpf.;Alexander Crispin.;Stephan Goerigk.;Elisabeth Andre.;Christian Plewnia.;Bettina Brendel.;Andreas Fallgatter.;Berthold Langguth.;Mohamed Abdelnaim.;Tobias Hebel.;Claus Normann.;Lukas Frase.;Peter Zwanzger.;Julia Diemer.;Thomas Kammer.;Carlos Schönfeldt-Lecuona.;Daniel Kamp.;Malek Bajbouj.;Nora Behler.;Anja Wilkening.;Tabea Nenov-Matt.;Esther Dechantsreiter.;Daniel Keeser.;Lucia Bulubas.;Ulrich Palm.;Christiane Blankenstein.;Ulrich Mansmann.;Peter Falkai.;Andre R Brunoni.;Alkomiet Hasan.;Frank Padberg.
来源: Lancet. 2023年402卷10401期545-554页
Transcranial direct current stimulation (tDCS) has been proposed as a feasible treatment for major depressive disorder (MDD). However, meta-analytic evidence is heterogenous and data from multicentre trials are scarce. We aimed to assess the efficacy of tDCS versus sham stimulation as an additional treatment to a stable dose of selective serotonin reuptake inhibitors (SSRIs) in adults with MDD.
3957. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019.
Communicable disease control has long been a focus of global health policy. There have been substantial reductions in the burden and mortality of communicable diseases among children younger than 5 years, but we know less about this burden in older children and adolescents, and it is unclear whether current programmes and policies remain aligned with targets for intervention. This knowledge is especially important for policy and programmes in the context of the COVID-19 pandemic. We aimed to use the Global Burden of Disease (GBD) Study 2019 to systematically characterise the burden of communicable diseases across childhood and adolescence.
3959. Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing.
作者: Ratna Wijaya.;Marina Johnson.;Nicola Campbell.;Beth Stuart.;Adam Kelly.;Nicole Tipler.;Tobias Menne.;Matthew J Ahearne.;Victoria Willimott.;Anna Bowzyk Al-Naeeb.;Christopher P Fox.;Graham P Collins.;Ann O'Callaghan.;Andrew J Davies.;David Goldblatt.;Sean H Lim.; .
来源: Lancet. 2023年402卷10396期99-102页 |